Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1089252 | 1.00 | ALDH1A1 (0.50) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL17628726 | 0.91 | ALDH1A1 (0.39) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL17628724 | 0.91 | ALDH1A1 (0.39) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL26217989 | 0.87 | ALDH1A1 (0.43) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL6858920 | 0.82 | ALDH1A1 (0.40) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL8073575 | 0.82 | ALDH1A1 (0.50) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL4138799 | 0.82 | NPC1 (0.50) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL7706555 | 0.81 | ALDH1A1 (0.39) | ALDH1A1NPC1SLC22A2SLC47A1MAPT | |
| SCHEMBL13148519 | 0.81 | DPP4 (0.48) | ALDH1A1NPC1DPP4CYP3A4 | |
| SCHEMBL1088842 | 0.81 | TSHR (0.42) | ALDH1A1NPC1SLC22A2SLC47A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2023-11-23 | — | — | US | disclosed |
| WO-2013111158-A2 | PROCESS FOR THE PREPARATION OF DPP-IV INHIBITOR | MSN LABORATORIES LIMITED (IN) | 2013-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372372-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | ALDH1A1 1198/4885NPC1 2369/4885SLC22A2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.